

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A process for determining IL-10 promoter alleles specific to an individual human, said process comprising the step of: genotyping DNA ~~encoding IL-10~~ -1.2 to -4.0 kb in an IL-10 promoter region for a single nucleotide polymorphism which affects IL-10 production, the single nucleotide polymorphism at a position selected from the group consisting of -3575 and -2763, said DNA being obtained from said individual human, said genotyping of said DNA resulting in determination of IL-10 promoter alleles specific to said individual human, wherein an A at position -3575 is associated with low IL-10 production, and wherein an A at position -2763 is associated with low IL-10 production.

Claims 2-8 (Canceled)

9. (Withdrawn) A commercial package comprising reagents for identifying a single nucleotide polymorphism in an IL-10 promoter genotype or phenotype together with instructions for the use thereof as a test to identify individual susceptibility to a disease.

10. (Withdrawn) A diagnostic for disease susceptibility comprising: an IL-10 promoter region -1.2 to -4.0 kb having a single nucleotide polymorphism therein.

11. (Withdrawn) The diagnostic of claim 10 wherein the single nucleotide polymorphism is selected from the group consisting of: -3575 T/A, -2849 G/A and -2763 C/A.

12. (New) The process of claim 1 wherein said genotyping is genotyping of the single nucleotide polymorphism at position -3575 and genotyping of the single nucleotide polymorphism at position -2763.

13. (New) The process of claim 11 further comprising the step of genotyping DNA in an IL-10 promoter region for a single nucleotide polymorphism at position -2849, thereby determining a haplotype at positions -3575, -2849 and -2763.

14. (New) The process of claim 12 wherein the haplotype A[G/A]A is associated with low IL-10 levels production.

15. (New) The process of claim 12 wherein the haplotype TGC is associated with high IL-10 production.